222 related articles for article (PubMed ID: 28756584)
21. Early Cost-effectiveness Analysis of Electrochemotherapy as a Prospect Treatment Modality for Skin Melanoma.
Pirc E; Federici C; Bošnjak M; Perić B; Reberšek M; Pecchia L; Glumac N; Čemažar M; Snoj M; Serša G; Miklavčič D
Clin Ther; 2020 Aug; 42(8):1535-1548.e2. PubMed ID: 32768246
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of therapies for melanoma.
Johnston KM; McPherson E; Osenenko K; Vergidis J; Levy AR; Peacock S
Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):229-42. PubMed ID: 25703441
[TBL] [Abstract][Full Text] [Related]
23. The health burden and economic costs of cutaneous melanoma mortality by race/ethnicity-United States, 2000 to 2006.
Ekwueme DU; Guy GP; Li C; Rim SH; Parelkar P; Chen SC
J Am Acad Dermatol; 2011 Nov; 65(5 Suppl 1):S133-43. PubMed ID: 22018062
[TBL] [Abstract][Full Text] [Related]
24. The burden of metastatic melanoma: treatment patterns, healthcare use (utilization), and costs.
Reyes C; DaCosta Byfield S; Linke R; Satram-Hoang S; Teitelbaum AH
Melanoma Res; 2013 Apr; 23(2):159-66. PubMed ID: 23370422
[TBL] [Abstract][Full Text] [Related]
25. Melanoma treatment costs: a systematic review of the literature, 1990-2011.
Guy GP; Ekwueme DU; Tangka FK; Richardson LC
Am J Prev Med; 2012 Nov; 43(5):537-45. PubMed ID: 23079178
[TBL] [Abstract][Full Text] [Related]
26. [Descriptive study of the costs of diagnosis and treatment of cutaneous melanoma].
Almazán-Fernández FM; Serrano-Ortega S; Moreno-Villalonga JJ
Actas Dermosifiliogr; 2009 Nov; 100(9):785-91. PubMed ID: 19889300
[TBL] [Abstract][Full Text] [Related]
27. Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: results from a retrospective, longitudinal survey (MELODY study).
Johnston K; Levy AR; Lorigan P; Maio M; Lebbe C; Middleton M; Testori A; Bédane C; Konto C; Dueymes A; Sbarigia U; van Baardewijk M
Eur J Cancer; 2012 Sep; 48(14):2175-82. PubMed ID: 22480965
[TBL] [Abstract][Full Text] [Related]
28. Specialized surveillance for individuals at high risk for melanoma: a cost analysis of a high-risk clinic.
Watts CG; Cust AE; Menzies SW; Coates E; Mann GJ; Morton RL
JAMA Dermatol; 2015 Feb; 151(2):178-86. PubMed ID: 25389712
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of adding FDG-PET or CT to the diagnostic work-up of patients with stage III melanoma.
Bastiaannet E; Uyl-de Groot CA; Brouwers AH; van der Jagt EJ; Hoekstra OS; Oyen W; Verzijlbergen F; van Ooijen B; Thompson JF; Hoekstra HJ
Ann Surg; 2012 Apr; 255(4):771-6. PubMed ID: 22367443
[TBL] [Abstract][Full Text] [Related]
30. Costs of illness for melanoma and nonmelanoma skin cancer in Denmark.
Bentzen J; Kjellberg J; Thorgaard C; Engholm G; Phillip A; Storm HH
Eur J Cancer Prev; 2013 Nov; 22(6):569-76. PubMed ID: 23542376
[TBL] [Abstract][Full Text] [Related]
31. Cost-of-illness of melanoma in Europe - a modelling approach.
Krensel M; Schäfer I; Augustin M
J Eur Acad Dermatol Venereol; 2019 Mar; 33 Suppl 2():34-45. PubMed ID: 30811699
[TBL] [Abstract][Full Text] [Related]
32. Prevalence and costs of skin cancer treatment in the U.S., 2002-2006 and 2007-2011.
Guy GP; Machlin SR; Ekwueme DU; Yabroff KR
Am J Prev Med; 2015 Feb; 48(2):183-187. PubMed ID: 25442229
[TBL] [Abstract][Full Text] [Related]
33. NICE guidance for talimogene laherparepvec for unresectable metastatic melanoma.
Adam J; Robertson J; Donegan E; Voicechovskaja I
Lancet Oncol; 2016 Nov; 17(11):1485-1486. PubMed ID: 27692478
[No Abstract] [Full Text] [Related]
34. Stage-specific direct health care costs in patients with cutaneous malignant melanoma.
Lyth J; Carstensen J; Synnerstad I; Lindholm C
J Eur Acad Dermatol Venereol; 2016 May; 30(5):789-93. PubMed ID: 25807966
[TBL] [Abstract][Full Text] [Related]
35. Economic burden of melanoma in the elderly population: population-based analysis of the Surveillance, Epidemiology, and End Results (SEER)--Medicare data.
Seidler AM; Pennie ML; Veledar E; Culler SD; Chen SC
Arch Dermatol; 2010 Mar; 146(3):249-56. PubMed ID: 20231494
[TBL] [Abstract][Full Text] [Related]
36. Diagnosis and management costs of suspicious skin lesions from a population-based melanoma screening programme.
Gordon L; Youl PH; Elwood M; Janda M; Ring IT; Lowe JB; Aitken JF
J Med Screen; 2007; 14(2):98-102. PubMed ID: 17626710
[TBL] [Abstract][Full Text] [Related]
37. Whole Grain Intakes Are Associated with Healthcare Cost Savings Following Reductions in Risk of Colorectal Cancer and Total Cancer Mortality in Australia: A Cost-of-Illness Model.
Abdullah MMH; Hughes J; Grafenauer S
Nutrients; 2021 Aug; 13(9):. PubMed ID: 34578860
[TBL] [Abstract][Full Text] [Related]
38. Estimating the healthcare costs of treating prostate cancer in Australia: A Markov modelling analysis.
Gordon LG; Tuffaha HW; James R; Keller AT; Lowe A; Scuffham PA; Gardiner RA
Urol Oncol; 2018 Mar; 36(3):91.e7-91.e15. PubMed ID: 29169847
[TBL] [Abstract][Full Text] [Related]
39. Economic evaluation of an educational campaign for early diagnosis of cutaneous melanoma.
Garattini L; Cainelli T; Tribbia G; Scopelliti D
Pharmacoeconomics; 1996 Feb; 9(2):146-55. PubMed ID: 10160093
[TBL] [Abstract][Full Text] [Related]
40. [Economic aspects of diagnosis, treatment and rehabilitation of patients with malignant skin neoplasms].
Stranadko EF; Aleksandrova LA; Khadzhiev MA
Sov Med; 1990; (9):39-40. PubMed ID: 2148438
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
